Drugs and patents in ATC class A11H - OTHER PLAIN VITAMIN PREPARATIONS

Last updated: June 7, 2026

Executive summary

ATC A11H covers plain (single-ingredient) vitamins and vitamin-like actives that do not fall in more specific ATC vitamin subclasses (eg, “other plain vitamin preparations”).
Patent coverage is highly fragmented by active ingredient and dosage form, with the most durable IP typically coming from:
- Controlled-release/extended-release (CR/XR) formulations
- Stabilized compositions (light, oxygen, moisture)
- Combination technologies (even when marketed as “plain,” many products use excipient and stabilization systems)
- Manufacturing process patents (drying, granulation, encapsulation)
Regulatory exclusivity is usually weak to moderate for “plain vitamin” categories because many vitamin actives are old and widely generic. The competitive battleground is usually Orange Book “listed patents” (if any) tied to a specific NDA/ANDAs rather than broad, class-wide primary patents.
For forecasting and licensing, the market should be treated as a portfolio of individual actives inside A11H rather than a single IP universe. The patent landscape and launch risk are therefore ingredient-specific.

Which vitamins fall under ATC A11H “other plain vitamin preparations,” and what does that mean for IP?

Featured snippet answer: A11H is a catch-all for plain vitamin products not classified elsewhere within ATC vitamin groupings, so the IP landscape is driven by the specific vitamin active and the branded formulation/NDA tied to it, not by a single class patent.

Subcategory structure that drives patent mapping

A11H is operationally treated as:

Active ingredient-led mapping (each vitamin has distinct historical patent coverage and formulation IP)
Dosage form-led mapping (tablets, capsules, effervescents, chewables, drops, sachets, sustained release)

This matters because the strongest enforceable patents in vitamins tend to be formulation and method-of-manufacture rather than the chemical entity, which is generally off-patent.

How this changes the market’s “patent logic”

If the active ingredient is old, entity patents have expired.
Remaining value often comes from:
- shelf-life and stability
- taste/mouthfeel for oral solids
- bioavailability improvements through excipient systems
- CR/XR profiles that support differentiation

How do patents typically protect plain vitamins in A11H versus new drug classes?

Featured snippet answer: In A11H, patents usually protect formulations, delivery systems, and manufacturing processes rather than the vitamin molecule itself.

Patent categories that show up most often

Formulation patents
- Stabilized compositions (oxygen/moisture/light protection)
- Protected encapsulation (microencapsulation, lipid systems)
- Effervescent systems with pH and CO2 control
- Tablets/capsules with excipient blends designed for stability or dissolution
Dosage form and release mechanism patents
- CR/XR matrix systems
- Triggered release (pH dependent)
- Multi-layer tablets
Manufacturing process patents
- Granulation, blending, and drying conditions
- Encapsulation and coating processes
- Scale-up/quality-by-design methods
Method-of-use patents
- In vitamins, method-of-use can be limited because many labels already support general supplementation.
- When present, it is usually tied to a specific subpopulation or dose regimen.

Practical implication for freedom-to-operate (FTO)

A generic entrant’s risk is often not “does the vitamin work,” but:
- Is the exact formulation protected
- Is a specific release profile required
- Is a stabilization technology being copied

When do A11H vitamin products lose exclusivity, and what drives the timing?

Featured snippet answer: Exclusivity timing is mostly driven by the specific NDA/505(b)(2) approval date and Orange Book “listed patents,” not by ATC class-level protections.

What “exclusivity” looks like in vitamins

Many vitamin actives have no meaningful patent runway left.
Where there is protection, it tends to follow one of these patterns:
- New dosage form on an NDA with listed patents
- New formulation strategy (CR/XR or stability) that attracted patenting
- 505(b)(2) pathways where an innovator relies on published literature plus new formulation changes

Forecasting approach for market dynamics

For each marketed vitamin product in A11H, the critical dates are:

NDA approval date (and if 505(b)(2), the exclusivity tied to reference listed drugs or data)
Orange Book patent list dates (filing, expiration, PTA if any)
Any granted or litigated patent term adjustments or extensions at the product level

Timing metrics that matter to investors and BD

First potential Paragraph IV window (if an NDA has listed Orange Book patents)
Expected generic launch timeline post-expiration:
- 180-day exclusivity possibility
- Settlement-triggered timing
- Practical manufacturing tech transfer

What patents cover plain vitamin formulations in the Orange Book, and how many are usually listed?

Featured snippet answer: A11H products that appear in the Orange Book typically list a small number of patents per NDA/strength, with the most common remaining protections being formulation and composition-of-matter for that specific product plus sometimes method-of-use.

Typical patent “shape” for A11H

Composition/formulation patents: often the largest set
Process patents: smaller sets, but enforceable
Method-of-use: fewer
Device/patient handling: usually absent because these are oral supplements

How many is “small” in practice

In vitamin portfolios, the common pattern is:

Fewer than 10 listed patents per marketed presentation where Orange Book coverage exists.
Sometimes 0 listed patents if the brand is old and never listed or if the listed patents are fully expired.

What is the Orange Book status of A11H vitamin products, and how does it affect generic entry risk?

Featured snippet answer: Orange Book status determines whether FDA approval for a generic/ANDA can trigger Paragraph IV litigation; many A11H products face low litigation risk because there are no unexpired listed patents, but some still have unexpired formulation patents.

Generic entry risk drivers in A11H

Unexpired Orange Book patents tied to the brand presentation
Satisfying bioequivalence when the innovator has CR/XR complexity
Excipients and stability that are hard to match and may drive carve-outs or regulatory differences

Litigation pattern differences from oncology or biologics

Fewer “bet-the-company” lawsuits tied to new chemical entities.
More frequent settlement-driven timing disputes tied to formulation replication.

Which companies are challenging A11H vitamin patents, and what settlement dynamics dominate?

Featured snippet answer: In A11H, generic challengers are usually established ANDA filers with vitamin portfolios; settlements typically focus on design-around and launch timing for specific presentations.

Settlement and design-around tendencies

Settlements in plain vitamins often include:

Launch date covenants
Strength/formulation carve-outs
Exclusivity allocation through 180-day mechanisms where available
Non-infringement or stipulated non-infringement findings tied to formulation differences

Portfolio behavior

Market participants often treat A11H as:
- a steady-volume category with recurring launches
- a competitive field where pricing erodes quickly after generic entry
Patent value is concentrated in product-specific CR/XR and stability rather than broad class claims.

How strong is the patent estate for A11H vitamins, and which patent types hold up best?

Featured snippet answer: Patent strength is usually highest for formulation/delivery system claims tied to specific product characteristics; chemical entity claims are typically expired or weak as a basis for long-term exclusivity.

Strength indicators to evaluate during DD or licensing

Claim scope vs. design-around feasibility
- If claims cover only a narrow excipient range or specific coating process, generic design-around is easier.
Enablement and written description
- Formulation patents can be vulnerable if claims are broader than examples.
Infringement feasibility
- CR/XR and encapsulation tech can be harder to prove in vitro without matching key parameters.
Litigation history
- Repeated invalidation outcomes in similar vitamin formulation cases indicate systemic vulnerability.

Practical rating rubric for BD teams

High: composition and manufacturing-process patents that map directly to protected parameters likely used in the brand and can be tested in ANDA comparisons.
Medium: formulation patents with broad ranges but uncertain proof of infringement.
Low: “method-of-use” claims where label already covers broad supplementation and where clinical endpoints are not central.

What formulations are protected by A11H patents, and where do design-arounds concentrate?

Featured snippet answer: The most protectable and litigated areas are release behavior, stabilization systems, and encapsulation/coating technologies; design-arounds concentrate in excipient composition and process parameters that change stability and dissolution.

Protected formulation themes

Stabilized vitamin compositions
- oxygen/moisture control
- antioxidant-coordination systems
- light protection via coating or packaging system interfaces
CR/XR delivery
- matrix chemistry and particle size distributions
- coating thickness and layering
Taste and mouthfeel systems (especially chewables)
- masking technologies and granulation approaches

Design-around hotspots for generics

Replace patented excipient combinations with alternatives that maintain:
- stability
- dissolution profile
- bioequivalence
Adjust particle size distribution and granulation route
Change coating method to alter dissolution without altering active exposure within BE ranges

How does A11H compare with other vitamin ATC classes on patent durability and competition?

Featured snippet answer: A11H generally has shorter patent durability because it is populated by older, off-entity-expiration vitamins; competitive pressure is high and differentiation shifts to formulation-based IP where present.

Where durability tends to be stronger or weaker

Stronger durability: if a subset includes newer dosage forms or technically complex stabilization systems that were patented after generic saturation.
Weaker durability: plain immediate-release tablets/capsules where multiple ANDAs already match and the market trades primarily on price.

Competitive landscape implication

Brand premiums collapse quickly post-generic entry unless:
- patents block entry for a specific presentation
- superior stability or patient experience maintains brand loyalty

What generic entry risks exist for A11H vitamin products?

Featured snippet answer: Entry risks are highest when the brand has unexpired Orange Book formulation patents for a specific strength and release profile; lower when the brand has no listed patents or patents have expired.

Risk matrix (product-level)

High risk: unexpired composition/formulation patents + complex CR/XR + BE requires matching dissolution kinetics.
Medium risk: unexpired patents but claims are narrow or infringement proof is uncertain.
Low risk: no unexpired Orange Book patents or patents expired; competition is pricing-focused.

Operational risk for ANDA filers

Formulation replication and stability data requirements can be the bottleneck, not simply legal freedom.
CR/XR and encapsulated systems can require process development that may be “close” to patented methods.

What FDA regulatory pathway issues shape A11H patent challenges and launch timing?

Featured snippet answer: The regulatory pathway (ANDAs with Paragraph IV vs 505(b)(2) dependencies) determines whether patent challenges occur; bioequivalence requirements and product-specific stability/dissolution specs shape practical launch timing.

Common pathways that affect timing

ANDA (generic) relies on BE and listed reference product
505(b)(2) may exploit literature but is still tied to protected data in rare cases and often brings its own patent list dynamics

Practical timeline impacts

If a brand product has CR/XR or specialized stability, ANDA development timelines extend, even if legal barriers are reduced.
If patents are settled, the legal block can be the dominant factor, but manufacturing readiness still determines launch dates.

Key Takeaways

A11H is a portfolio of plain vitamin actives; the patent landscape is ingredient- and presentation-specific, not class-wide.
Formulation, stabilization, and delivery technologies drive the remaining enforceable IP in many A11H cases; the vitamin molecules themselves are generally off-patent.
Orange Book status at the NDA presentation level is the primary determinant of generic entry risk and Paragraph IV litigation.
Market dynamics follow patent durability only where unexpired listed patents remain; otherwise, competition is price-driven with rapid generic erosion.

FAQs

Do plain vitamins in A11H qualify for Paragraph IV challenges even when the molecule is off-patent?
Yes, if the branded NDA lists unexpired Orange Book patents tied to formulation or dosage form.
Are CR/XR vitamin formulations more patent-protected than immediate-release tablets?
Typically yes, because release mechanisms and stabilization parameters are more likely to be patented and copied with difficulty.
Do method-of-use patents for vitamin supplementation materially affect generic entry in A11H?
Less often than formulation patents, but they can matter when claims match the label regimen of the reference product and remain unexpired.
How do packaging and stability patents interact with oral vitamin product patent estates?
If packaging-related claims are tied to product performance or composition systems, they can influence design-around and enforcement, though many stability advantages are achieved through formulation rather than packaging alone.
What’s the main reason A11H patent litigation differs from biologics and oncology?
Litigation is generally driven by product-specific formulation patents and Orange Book listings, not by broad entity protection or complex clinical exclusivities.

References

FDA. Orange Book: Approved Drug Products with Therapeutapeutic Equivalence Evaluations. (U.S. FDA).
World Health Organization. ATC Classification System. (ATC/WHO).

Subclasses in ATC: A11H - OTHER PLAIN VITAMIN PREPARATIONS